{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T20:26:04Z","timestamp":1770063964232,"version":"3.49.0"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostaglandins & Other Lipid Mediators"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.prostaglandins.2024.106946","type":"journal-article","created":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T06:44:04Z","timestamp":1735454644000},"page":"106946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Innovative approaches to eczema treatment: A review of Fevipiprant and its potential as a new therapeutic agent"],"prefix":"10.1016","volume":"176","author":[{"given":"Rahul","family":"Jaiswal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sageer","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supriya","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupali","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reetu","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reema","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabiya","family":"Ahsan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tapasya","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prostaglandins.2024.106946_bib1","doi-asserted-by":"crossref","unstructured":"Wollenberg, A., Christen-Z\u00e4ch, S., Taieb, A., Paul, C., Thyssen, J.P., de Bruin-Weller, M., \u2026 & European Task Force on Atopic Dermatitis\/EADV Eczema Task Force. (2020). ETFAD\/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. Journal of the European Academy of Dermatology and Venereology, 34(12), 2717-2744.","DOI":"10.1111\/jdv.16892"},{"issue":"3","key":"10.1016\/j.prostaglandins.2024.106946_bib2","first-page":"251","volume":"159","author":"Argenziano","year":"2024","journal-title":"Ital. J. Dermatol. Venereol."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.18345","article-title":"Euroguiderm guideline on atopic eczema","author":"Wollenberg","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib4","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2147\/TCRM.S292504","article-title":"Drugs for the treatment of chronic hand eczema: successes and key challenges","author":"Dubin","year":"2020","journal-title":"Ther. Clin. Risk Manag."},{"issue":"6","key":"10.1016\/j.prostaglandins.2024.106946_bib5","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.jaip.2020.02.022","article-title":"Endophenotypic variations of atopic dermatitis by age, race, and ethnicity","volume":"8","author":"Nomura","year":"2020","journal-title":"J. Allergy Clin. Immunol.\u00a0Pract."},{"issue":"6","key":"10.1016\/j.prostaglandins.2024.106946_bib6","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.jaad.2021.11.018","article-title":"Improving quality of teledermatology visits: the skin-know-implement-next checklist","volume":"86","author":"Patel","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.prostaglandins.2024.106946_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/jcm11010085","article-title":"Vital and nonvital pulp therapy in primary dentition: an umbrella review","volume":"11","author":"Lopes","year":"2021","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.prostaglandins.2024.106946_bib8","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1172\/JCI21060","article-title":"New insights into atopic dermatitis","volume":"113","author":"Leung","year":"2004","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.prostaglandins.2024.106946_bib9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jaad.2017.09.074","article-title":"A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis","volume":"78","author":"Sherry","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.prostaglandins.2024.106946_bib10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/DER.0000000000000798","article-title":"Contact allergy cross-reactions and thresholds: a review","volume":"33","author":"Scheman","year":"2022","journal-title":"Dermatitis"},{"key":"10.1016\/j.prostaglandins.2024.106946_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000358606","article-title":"Atopic dermatitis\/atopic eczema","volume":"100","author":"Wallach","year":"2014","journal-title":"Hist. Allergy"},{"key":"10.1016\/j.prostaglandins.2024.106946_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106250","article-title":"The triad of current asthma, rhinitis and eczema is uncommon among adults: prevalence, sensitization profiles, and risk factors","volume":"176","author":"Pullerits","year":"2021","journal-title":"Respir. Med."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40521-020-00271-x","article-title":"Filaggrin gene mutations with special reference to atopic dermatitis","volume":"7","author":"Gupta","year":"2020","journal-title":"Curr. Treat. Options Allergy"},{"issue":"2","key":"10.1016\/j.prostaglandins.2024.106946_bib14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3390\/jcm10020233","article-title":"Filaggrin loss-of-function mutations are risk factors for severe food allergy in children with atopic dermatitis","volume":"10","author":"Astolfi","year":"2021","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.prostaglandins.2024.106946_bib15","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/cod.13572","article-title":"Hyperkeratotic hand eczema: eczema or not?","volume":"83","author":"Politiek","year":"2020","journal-title":"Contact Dermat."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib16","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1684\/ejd.2020.3769","article-title":"Differential histopathological and immunohistochemical findings between palmar psoriasis and chronic hand eczema","volume":"30","author":"An","year":"2020","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib17","doi-asserted-by":"crossref","unstructured":"Akdis, C.A., Arkwright, P.D., Br\u00fcggen, M.C., Busse, W., Gadina, M., Guttman-Yassky, E., \u2026 & Palomares, O. (2020). Type 2 immunity in the skin and lungs. Allergy, 75(7), 1582-1605.","DOI":"10.1111\/all.14318"},{"issue":"8","key":"10.1016\/j.prostaglandins.2024.106946_bib18","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.3390\/jcm12083043","article-title":"Potential role of innate lymphoid cells in the pathogenesis and treatment of skin diseases","volume":"12","author":"Borgia","year":"2023","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.prostaglandins.2024.106946_bib19","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1080\/09546634.2021.1925077","article-title":"The prevention effect of probiotics against eczema in children: an update systematic review and meta-analysis","volume":"33","author":"Sun","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib20","doi-asserted-by":"crossref","unstructured":"Eichenfield, L.F., Kusari, A., Han, A.M., Barbarot, S., Deleuran, M., Lio, P., \u2026 & Stalder, J.F. (2021). Therapeutic education in atopic dermatitis: A position paper from the International Eczema Council.","DOI":"10.1016\/j.jdin.2021.01.001"},{"key":"10.1016\/j.prostaglandins.2024.106946_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.718002","article-title":"Biochemical and structural characteristics, gene regulation, physiological, pathological and clinical features of lipocalin-type prostaglandin D2 synthase as a multifunctional lipocalin","volume":"12","author":"Urade","year":"2021","journal-title":"Front. Physiol."},{"issue":"1","key":"10.1016\/j.prostaglandins.2024.106946_bib22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13567-022-01100-6","article-title":"Anti-inflammatory effects of the prostaglandin D2\/prostaglandin DP1 receptor and lipocalin-type prostaglandin D2 synthase\/prostaglandin D2 pathways in bacteria-induced bovine endometrial tissue","volume":"53","author":"Wu","year":"2022","journal-title":"Vet. Res."},{"issue":"4","key":"10.1016\/j.prostaglandins.2024.106946_bib23","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1248\/bpb.b19-00838","article-title":"Induced prostanoid synthesis regulates the balance between Th1-and Th2-producing inflammatory cytokines in the thymus of diet-restricted mice","volume":"43","author":"Razali","year":"2020","journal-title":"Biol. Pharm. Bull."},{"issue":"4","key":"10.1016\/j.prostaglandins.2024.106946_bib24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/14656566.2020.1829593","article-title":"Current and emerging pharmacotherapy for chronic spontaneous urticaria: a focus on non-biological therapeutics","volume":"22","author":"Hon","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40261-020-00905-7","article-title":"Revisiting therapies for atopic dermatitis that failed clinical trials","volume":"40","author":"Agnihotri","year":"2020","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103181","article-title":"A reverse translational approach reveals the protective roles of Mangifera indica in inflammatory bowel disease","volume":"144","author":"Saviano","year":"2024","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.yjmcc.2022.03.011","article-title":"Prostaglandin D2 signaling and cardiovascular homeostasis","volume":"167","author":"Kong","year":"2022","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib28","doi-asserted-by":"crossref","unstructured":"Kourentas, A., Gajewska, M., Lin, W., Dhareshwar, S.S., Steib-Lauer, C., Kulkarni, S., \u2026 & Mueller-Zsigmondy, M. (2023). Establishing the safe space via physiologically based biopharmaceutics modeling. Case study: Fevipiprant\/QAW039. The AAPS Journal, 25(1), 25.","DOI":"10.1208\/s12248-023-00787-5"},{"key":"10.1016\/j.prostaglandins.2024.106946_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2021.102030","article-title":"The pharmacology of the prostaglandin D2 receptor 2 (DP2) receptor antagonist, fevipiprant","volume":"68","author":"Brightling","year":"2021","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.prostaglandins.2024.106946_bib30","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1080\/13543784.2022.2078192","article-title":"Pharmacokinetics, safety, and tolerability of TQC3564, a novel CRTh2 receptor antagonist: report of the first-in-human single-and multiple-dose escalation trials in healthy Chinese subjects","volume":"31","author":"Li","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"7","key":"10.1016\/j.prostaglandins.2024.106946_bib31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11882-021-01017-8","article-title":"Efficacy and safety of prostaglandin D2 receptor 2 antagonism with fevipiprant for patients with asthma: a systematic review and meta-analysis of randomized controlled trials","volume":"21","author":"Yang","year":"2021","journal-title":"Curr. Allergy Asthma Rep."},{"issue":"7908","key":"10.1016\/j.prostaglandins.2024.106946_bib32","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41586-022-04630-3","article-title":"Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19","volume":"605","author":"Wong","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.prostaglandins.2024.106946_bib33","article-title":"A dual role for CRTH2 in acute lung injury","author":"Jung","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.prostaglandins.2024.106946_bib34","first-page":"55","article-title":"LUSTER-1 and-2: two randomized controlled trials of the prostaglandin D2 receptor 2 antagonist, fevipiprant, in asthma","volume":"9","author":"Brightling","year":"2019","journal-title":"Clin. Invest."},{"issue":"1","key":"10.1016\/j.prostaglandins.2024.106946_bib35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev-immunol-110119-091711","article-title":"Group 2 innate lymphoid cells: team players in regulating asthma","volume":"39","author":"Rodriguez-Rodriguez","year":"2021","journal-title":"Annu. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.prostaglandins.2024.106946_bib36","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1124\/dmd.117.075358","article-title":"Absorption, distribution, metabolism, and excretion of the oral prostaglandin D2 receptor 2 antagonist fevipiprant (QAW039) in healthy volunteers and in vitro","volume":"45","author":"Pearson","year":"2017","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.prostaglandins.2024.106946_bib37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/13543784.2019.1555237","article-title":"Prostaglandin D2 receptor antagonists in allergic disorders: safety, efficacy, and future perspectives","volume":"28","author":"Marone","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"18","key":"10.1016\/j.prostaglandins.2024.106946_bib38","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1080\/14656566.2018.1540589","article-title":"An evaluation of fevipiprant for the treatment of asthma: a promising new therapy?","volume":"19","author":"Murillo","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib39","article-title":"Innate immune cells in tumour microenvironment: a new frontier in cancer immunotherapy","author":"Li","year":"2024","journal-title":"Iscience"},{"key":"10.1016\/j.prostaglandins.2024.106946_bib40","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00011-021-01438-1","article-title":"Potential of anthocyanin as an anti-inflammatory agent: a human clinical trial on type 2 diabetic, diabetic at-risk and healthy adults","volume":"70","author":"Nikbakht","year":"2021","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2024.01.015","article-title":"The mucosal concept in chronic rhinosinusitis: focus on the epithelial barrier","author":"Yan","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"issue":"9","key":"10.1016\/j.prostaglandins.2024.106946_bib42","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3390\/vaccines10091380","article-title":"The roles of skin Langerhans cells in immune tolerance and cancer immunity","volume":"10","author":"Zhou","year":"2022","journal-title":"Vaccines"},{"issue":"8","key":"10.1016\/j.prostaglandins.2024.106946_bib43","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.3390\/pharmaceutics15082105","article-title":"Radiosterilized pig skin, silver nanoparticles and skin cells as an integral dressing treatment for burns: development, pre-clinical and clinical pilot study","volume":"15","author":"Ortega-S\u00e1nchez","year":"2023","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.prostaglandins.2024.106946_bib44","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/cts.13455","article-title":"The randomized, single-and multiple-ascending dose studies of the safety, tolerability, pharmacokinetics of CSPCHA115 in healthy Chinese subjects","volume":"16","author":"Jing","year":"2023","journal-title":"Clin. Transl. Sci."},{"issue":"5","key":"10.1016\/j.prostaglandins.2024.106946_bib45","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/dmd.120.000273","article-title":"Clinical investigation of metabolic and renal clearance pathways contributing to the elimination of fevipiprant using probenecid as perpetrator","volume":"49","author":"Weiss","year":"2021","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.prostaglandins.2024.106946_bib46","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/1389201021666200611112755","article-title":"Novel therapeutic approaches and targets for the treatment of atopic dermatitis","volume":"22","author":"Pescitelli","year":"2021","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"1","key":"10.1016\/j.prostaglandins.2024.106946_bib47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic dermatitis: an expanding therapeutic pipeline for a complex disease","volume":"21","author":"Bieber","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.prostaglandins.2024.106946_bib48","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3515","article-title":"A therapeutic renaissance\u2013emerging treatments for atopic dermatitis","volume":"100","author":"Na","year":"2020","journal-title":"Acta Derm. Venereol."},{"issue":"1","key":"10.1016\/j.prostaglandins.2024.106946_bib49","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/1389201021666200611112755","article-title":"Novel therapeutic approaches and targets for the treatment of atopic dermatitis","volume":"22","author":"Pescitelli","year":"2021","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"1","key":"10.1016\/j.prostaglandins.2024.106946_bib50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic dermatitis: an expanding therapeutic pipeline for a complex disease","volume":"21","author":"Bieber","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.prostaglandins.2024.106946_bib51","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol."},{"issue":"1","key":"10.1016\/j.prostaglandins.2024.106946_bib52","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/13543784.2019.1555237","article-title":"Prostaglandin D2 receptor antagonists in allergic disorders: safety, efficacy, and future perspectives","volume":"28","author":"Marone","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.prostaglandins.2024.106946_bib53","article-title":"Efficacy of biologics in NSAID-ERD: United airways from the nose to the bronchi","author":"Buchheit","year":"2024","journal-title":"J. Allergy Clin. Immunol.: Pract."},{"issue":"6","key":"10.1016\/j.prostaglandins.2024.106946_bib54","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jaci.2023.08.029","article-title":"Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials","volume":"152","author":"Chu","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"issue":"12","key":"10.1016\/j.prostaglandins.2024.106946_bib55","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3515","article-title":"A therapeutic renaissance\u2013emerging treatments for atopic dermatitis","volume":"100","author":"Na","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100847","article-title":"Efficacy and safety of fevipiprant in patients with uncontrolled asthma: two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2)","volume":"35","author":"Castro","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.prostaglandins.2024.106946_bib57","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S2213-2600(20)30412-4","article-title":"Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials","volume":"9","author":"Brightling","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"12","key":"10.1016\/j.prostaglandins.2024.106946_bib58","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3515","article-title":"A therapeutic renaissance\u2013emerging treatments for atopic dermatitis","volume":"100","author":"Na","year":"2020","journal-title":"Acta Derm. -Venereol."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib59","series-title":"In Allergic and Immunologic Diseases","first-page":"1111","article-title":"New biologics in allergy","author":"Lehman","year":"2022"},{"issue":"2","key":"10.1016\/j.prostaglandins.2024.106946_bib60","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/02611929231157756","article-title":"Poor translatability of biomedical research using animals-A narrative review","volume":"51","author":"Marshall","year":"2023","journal-title":"Altern. Lab. Anim."},{"issue":"4","key":"10.1016\/j.prostaglandins.2024.106946_bib61","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/all.14631","article-title":"Systemic treatments in the management of atopic dermatitis: a systematic review and meta-analysis","volume":"76","author":"Siegels","year":"2021","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.prostaglandins.2024.106946_bib62","doi-asserted-by":"crossref","first-page":"497","DOI":"10.5021\/ad.2021.33.6.497","article-title":"Consensus update for systemic treatment of atopic dermatitis","volume":"33","author":"Lee","year":"2021","journal-title":"Ann. Dermatol."},{"issue":"5","key":"10.1016\/j.prostaglandins.2024.106946_bib63","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s13555-023-00920-4","article-title":"Emerging systemic treatments for atopic dermatitis","volume":"13","author":"Ferrucci","year":"2023","journal-title":"Dermatol. Ther."},{"issue":"10","key":"10.1016\/j.prostaglandins.2024.106946_bib64","doi-asserted-by":"crossref","DOI":"10.1111\/cea.14188","article-title":"What is the most effective way to use topical corticosteroids for treating eczema?","volume":"52","author":"Banerjee","year":"2022","journal-title":"Clin. Exp. Allergy"},{"issue":"7","key":"10.1016\/j.prostaglandins.2024.106946_bib65","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-046476","article-title":"Safety of topical corticosteroids in atopic eczema: an umbrella review","volume":"11","author":"Axon","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.prostaglandins.2024.106946_bib66","author":"Moretz","year":"2021","journal-title":"Drug Cl. Update N. Drug Eval.\u00a0Top. Prod. Inflamm. Ski. Cond."},{"issue":"4","key":"10.1016\/j.prostaglandins.2024.106946_bib67","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/17425255.2024.2337749","article-title":"Clinical pharmacokinetics and pharmacodynamics of topical non-biological therapies for psoriasis patients","volume":"20","author":"Lo","year":"2024","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"3","key":"10.1016\/j.prostaglandins.2024.106946_bib68","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/1872211314999200819152450","article-title":"Recent approaches on novel topical delivery systems for atopic dermatitis treatment","volume":"14","author":"Kahraman","year":"2020","journal-title":"Recent Pat. Drug Deliv. Formul."},{"issue":"11","key":"10.1016\/j.prostaglandins.2024.106946_bib69","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/jdv.18429","article-title":"European guideline (EuroGuiDerm) on atopic eczema\u2013part II: non-systemic treatments and treatment recommendations for special AE patient populations","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"9","key":"10.1016\/j.prostaglandins.2024.106946_bib70","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/jdv.18345","article-title":"European guideline (EuroGuiDerm) on atopic eczema: part I\u2013systemic therapy","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib71","author":"Shrimanker","year":"2020","journal-title":"Manag. Mech. Sev. eosinophilic Asthma Dr. Diss., Univ. Oxf."},{"issue":"5","key":"10.1016\/j.prostaglandins.2024.106946_bib72","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3390\/molecules26051433","article-title":"Ramatroban-based analogues containing fluorine group as potential 18F-labeled positron emission tomography (PET) G-protein coupled receptor 44 (GPR44) tracers","volume":"26","author":"Huang","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.prostaglandins.2024.106946_bib73","doi-asserted-by":"crossref","unstructured":"Kurz, M., Ulrich, M., Bittner, A., & B\u00fcnemann, M. (2024). DP2 receptor activity sensor suited for antagonist screening and measurement of receptor dynamics in real-time. Scientific Reports, 14(1), 8178.","DOI":"10.1038\/s41598-024-58410-2"},{"issue":"9","key":"10.1016\/j.prostaglandins.2024.106946_bib74","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41573-023-00750-1","article-title":"Type 2 chronic inflammatory diseases: targets, therapies and unmet needs","volume":"22","author":"Kolkhir","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.prostaglandins.2024.106946_bib75","first-page":"1203","article-title":"Indole-based and cyclopentenylindole-based analogues containing fluorine group as potential 18F-labeled positron emission tomography (PET) G-protein coupled receptor 44 (GPR44)","volume":"16","author":"Yin","year":"2023","journal-title":"Tracers Pharm."},{"issue":"9","key":"10.1016\/j.prostaglandins.2024.106946_bib76","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1042\/CS20190281","article-title":"New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis","volume":"137","author":"Striz","year":"2023","journal-title":"Clin. Sci."},{"issue":"4","key":"10.1016\/j.prostaglandins.2024.106946_bib77","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jaci.2022.08.009","article-title":"Biologics for allergic and immunologic diseases","volume":"150","author":"Morita","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.prostaglandins.2024.106946_bib78","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.jaci.2021.12.759","article-title":"Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER)","volume":"149","author":"Gevaert","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104490","article-title":"New treatments for asthma: from the pathogenic role of prostaglandin D2 to the therapeutic effects of fevipiprant","volume":"155","author":"Pelaia","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib80","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jes.2023.02.005","article-title":"Role of inflammatory lipid and fatty acid metabolic abnormalities induced by plastic additives exposure in childhood asthma","volume":"137","author":"Chen","year":"2024","journal-title":"J. Environ. Sci."},{"issue":"1","key":"10.1016\/j.prostaglandins.2024.106946_bib81","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1186\/s12931-021-01904-8","article-title":"Long-term safety and exploratory efficacy of fevipiprant in patients with inadequately controlled asthma: the SPIRIT randomised clinical trial","volume":"22","author":"Maspero","year":"2021","journal-title":"Respir. Res."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib82","doi-asserted-by":"crossref","unstructured":"Akdis, C.A., Akdis, M., Bieber, T., Bindslev-Jensen, C., Boguniewicz, M., Eigenmann, P., \u2026 & Zuberbier, T. (2006). Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology\/American Academy of Allergy, Asthma and Immunology\/PRACTALL Consensus Report. Journal of allergy and clinical immunology, 118(1), 152-169.","DOI":"10.1016\/j.jaci.2006.03.045"},{"issue":"1","key":"10.1016\/j.prostaglandins.2024.106946_bib83","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.anai.2020.08.016","article-title":"New treatments in atopic dermatitis","volume":"126","author":"Puar","year":"2021","journal-title":"Ann. Allergy, Asthma Immunol."},{"issue":"10013","key":"10.1016\/j.prostaglandins.2024.106946_bib84","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Thaci","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.prostaglandins.2024.106946_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2005.01.010","article-title":"Adverse effects of topical glucocorticosteroids","volume":"54","author":"Hengge","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.prostaglandins.2024.106946_bib86","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/13543784.2019.1555237","article-title":"Prostaglandin D2 receptor antagonists in allergic disorders: safety, efficacy, and future perspectives","volume":"28","author":"Marone","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.prostaglandins.2024.106946_bib87","article-title":"Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study","volume":"373","author":"Li","year":"2021","journal-title":"bmj"},{"key":"10.1016\/j.prostaglandins.2024.106946_bib88","doi-asserted-by":"crossref","unstructured":"Li, X., Ostropolets, A., Makadia, R., Shaoibi, A., Rao, G., Sena, A.G., \u2026 & Prieto-Alhambra, D. (2021). Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study. Medrxiv, 2021-03.","DOI":"10.1101\/2021.03.25.21254315"},{"issue":"2","key":"10.1016\/j.prostaglandins.2024.106946_bib89","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jama.2022.9600","article-title":"Trends in adverse event rates in hospitalized patients, 2010-2019","volume":"328","author":"Eldridge","year":"2022","journal-title":"Jama"},{"issue":"14","key":"10.1016\/j.prostaglandins.2024.106946_bib90","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for adverse events after COVID-19 mRNA vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"Jama"},{"issue":"5","key":"10.1016\/j.prostaglandins.2024.106946_bib91","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.vaccine.2020.12.046","article-title":"Myopericarditis after vaccination, vaccine adverse event reporting system (VAERS), 1990\u20132018","volume":"39","author":"Su","year":"2021","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.prostaglandins.2024.106946_bib92","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/jdv.16948","article-title":"Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials","volume":"35","author":"Bieber","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112633","article-title":"Overcoming drug delivery barriers and challenges in topical therapy of atopic dermatitis: a nanotechnological perspective","volume":"147","author":"Hemrajani","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.prostaglandins.2024.106946_bib94","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/all.14690","article-title":"EAACI biologicals guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"issue":"11","key":"10.1016\/j.prostaglandins.2024.106946_bib95","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1164\/rccm.202005-1797RR","article-title":"Wiping out wheezing: novel therapeutic targets for patients with severe asthma","volume":"202","author":"Ramonell","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9","key":"10.1016\/j.prostaglandins.2024.106946_bib96","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(16)30179-5","article-title":"Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial","volume":"4","author":"Gonem","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"7","key":"10.1016\/j.prostaglandins.2024.106946_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0307750","article-title":"Prostaglandin D2 receptor 2 downstream signaling and modulation of type 2 innate lymphoid cells from patients with asthma","volume":"19","author":"Gress","year":"2024","journal-title":"Plos One"},{"issue":"1","key":"10.1016\/j.prostaglandins.2024.106946_bib98","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.anai.2019.10.005","article-title":"New treatments for atopic dermatitis targeting beyond IL-4\/IL-13 cytokines","volume":"124","author":"Renert-Yuval","year":"2020","journal-title":"Ann. Allergy, Asthma Immunol."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib99","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40261-020-00905-7","article-title":"Revisiting therapies for atopic dermatitis that failed clinical trials","volume":"40","author":"Agnihotri","year":"2020","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib100","doi-asserted-by":"crossref","DOI":"10.1080\/14712598.2024.2368192","article-title":"Monoclonal antibodies for moderate-to-severe atopic dermatitis: a look at phase III and beyond","author":"David","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib101","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2018.1544412","article-title":"Oral small molecules for the treatment of atopic dermatitis: a systematic review","author":"Mobasher","year":"2019","journal-title":"J. Dermatol. Treat."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib102","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40261-020-00905-7","article-title":"Revisiting therapies for atopic dermatitis that failed clinical trials","volume":"40","author":"Agnihotri","year":"2020","journal-title":"Clin. Drug Investig."},{"issue":"10","key":"10.1016\/j.prostaglandins.2024.106946_bib103","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1111\/all.14853","article-title":"Eczema herpeticum in atopic dermatitis","volume":"76","author":"Traidl","year":"2021","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.prostaglandins.2024.106946_bib104","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/DER.0000000000000598","article-title":"Impact of atopic dermatitis and chronic hand eczema on quality of life compared with other chronic diseases","volume":"31","author":"Capucci","year":"2020","journal-title":"Dermatitis"},{"issue":"11","key":"10.1016\/j.prostaglandins.2024.106946_bib105","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1111\/all.15058","article-title":"A new era of atopic eczema research: advances and highlights","volume":"76","author":"H\u00fclp\u00fcsch","year":"2021","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.prostaglandins.2024.106946_bib106","first-page":"590","article-title":"Atopic dermatitis: diagnosis and treatment","volume":"101","author":"Frazier","year":"2020","journal-title":"Am. Fam. Physician"},{"issue":"8","key":"10.1016\/j.prostaglandins.2024.106946_bib107","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.3390\/ijms22084130","article-title":"Molecular mechanisms of atopic dermatitis pathogenesis","volume":"22","author":"Sroka-Tomaszewska","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.prostaglandins.2024.106946_bib108","doi-asserted-by":"crossref","first-page":"7960","DOI":"10.3390\/ijms25147960","article-title":"The role of gamma delta t lymphocytes in physiological and pathological condition\u2014focus on psoriasis, atopic dermatitis, autoimmune disorders, cancer and lymphomas","volume":"25","author":"Chojnacka-Purpurowicz","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155664","article-title":"Novel pathogenesis of atopic dermatitis from the view of cytokines in mice and humans","volume":"148","author":"Nakajima","year":"2021","journal-title":"Cytokine"},{"key":"10.1016\/j.prostaglandins.2024.106946_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106308","article-title":"Relevance of tissue-resident memory CD8 T cells in the onset of Parkinson\u2019s disease and examination of its possible etiologies: infectious or autoimmune?","volume":"187","author":"de F\u00e0bregues","year":"2023","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.prostaglandins.2024.106946_bib111","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12974-023-02867-x","article-title":"Assessing the role of T cells in response to retinal injury to uncover new therapeutic targets for the treatment of retinal degeneration","volume":"20","author":"Conedera","year":"2023","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib112","article-title":"GZMK+\u2009CD8+\u2009T cells Target a Specific Acinar Cell Type in Sj\u00f6gren\u2019s Disease","author":"Warner","year":"2023","journal-title":"Res. Sq."},{"key":"10.1016\/j.prostaglandins.2024.106946_bib113","article-title":"Dual therapy with corticosteroid ablates the beneficial effect of DP2 antagonism in chronic experimental asthma","author":"Ullah","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.prostaglandins.2024.106946_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2021.102097","article-title":"Fevipiprant (QAW039) does not affect the pharmacokinetics of zidovudine, its glucuronide, and penicillin G via inhibition of UGT2B7 and\/or OAT3","volume":"72","author":"Kulkarni","year":"2022","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.prostaglandins.2024.106946_bib115","doi-asserted-by":"crossref","first-page":"98","DOI":"10.5114\/pja.2020.96130","article-title":"A summary of novel biologics for asthma treatment","volume":"7","author":"Dryga\u0142a","year":"2020","journal-title":"Alergol. Pol. Pol. J. Allergol."}],"container-title":["Prostaglandins & Other Lipid Mediators"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882324001400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882324001400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T21:57:09Z","timestamp":1737323829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098882324001400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":115,"alternative-id":["S1098882324001400"],"URL":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2024.106946","relation":{},"ISSN":["1098-8823"],"issn-type":[{"value":"1098-8823","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovative approaches to eczema treatment: A review of Fevipiprant and its potential as a new therapeutic agent","name":"articletitle","label":"Article Title"},{"value":"Prostaglandins & Other Lipid Mediators","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2024.106946","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106946"}}